Physician profile
Mark K Jordan
NPI 1922002252
$2,886.74
in general payments reported to CMS, 2019-2025
18 companies · $371 in 2025
The $371 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.83 · 2020: $64.28 · 2021: $475 · 2022: $157 · 2023: $336 · 2024: $1,408 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,249 · Travel and Lodging: $859 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.51 |
| Travel and Lodging | $858.85 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,054.82 | 2024 | Onyx Frontier |
| Janssen Pharmaceuticals, INC | $383.04 | 2019-2023 | Xarelto |
| Abbott Laboratories | $329.35 | 2021-2024 | Coroflow |
| Amgen INC. | $308.71 | 2023-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $240.93 | 2021-2025 | |
| Shockwave Medical, INC | $146.62 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $86.36 | 2022-2025 | Camzyos |
| Pfizer INC. | $62.03 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $54.92 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.65 | 2025 | Jardiance |
| Esperion Therapeutics, INC. | $35.26 | 2025 | Nexletol |
| Merck Sharp & Dohme LLC | $31.74 | 2022-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $29.56 | 2025 | Farxiga |
| Acist Medical Systems, INC. | $27.17 | 2024 | |
| Octapharma USA, INC. | $26.12 | 2025 | Fibryga |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $18.98 | 2024 | Rybelsus, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.48 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.